Cancer as neoplastic disorder is a collection of diseases in which cells can have various properties such as aggressive, invasive and/or metastasizing. These three malignant properties of cancer are their differentiative parts from benign tumours, which are self-limited in their growth and do not invade or metastasize [1]. Despite high advances in diagnosis and treatment of neoplastic diseases, overall survival and cure of patients still remains poor. Until recent years, surgery, chemotherapy, radiotherapy, and hormonal therapy have been the standard and routine therapeutic options available for patients. This has improved and supported survival in several types of solid tumours (breast cancer, prostate carcinoma) but drug toxicity related to chemotherapy and emergence of drug resistance in tumours has been the major cause of morbidity and mortality. Rapid scientific advances in cell biology in recently have enhanced our comprehension of the molecular mechanism of cancer and consequently increased the capability of scientists for anticancer drug design and discovery [2]. Targeted therapies like inhibition of overexpressed receptor/enzymes in some tumours have become one of the latest innovative trends in the treatment of cancer. Attempt to inhibit a specific molecular target that is hypothesized to have a pivotal role in a growth or progression of a specific tumor is a logical and so effective strategy for combating cancer [3]. Tyrosine kinases have been recognized as a new promising molecular target for treatment of cancer. Cell division and differentiation are important phenomenon in cells that regulate by signal transduction associated with receptor tyrosine kinases [2,4]. Incidence of some types of cancer is associated with mutation in genes

No abstract

No abstract